Detalles de la búsqueda
1.
Longitudinal changes in measles antibody titers in plasma donors and minimum antibody levels of immunoglobulin products for treatment of primary immunodeficiency.
Transfusion
; 58 Suppl 3: 3065-3071, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30536437
2.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
J Peripher Nerv Syst
; 18(2): 130-40, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23781960
3.
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Clin Immunol
; 139(2): 133-41, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21353644
4.
Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.
J Clin Immunol
; 31(5): 752-61, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21674136
5.
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
J Clin Immunol
; 30(5): 734-45, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20454851
6.
Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
J Clin Immunol
; 27(5): 503-9, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17479360
Resultados
1 -
6
de 6
1
Próxima >
>>